Scholarlink

<p>This study aimed to evaluate the outcomes of second haploidentical hematopoietic stem cell transplantation (HID-HSCT) for patients with severe aplastic anaemia (SAA) who experienced graft failure. Twenty-one SAA patients with graft failure after first allogeneic (allo-) HSCT were enrolled, including 6 (28.6%) with poor graft function and 15 (71.4%) with graft rejection. Two patients developed primary graft failure after the second transplantation, and the cumulative incidence of neutrophil recovery was 81.0% ± 0.9%, with a median recovery of 13 days (range, 10–23 days). The cumulative incidences of grade II–IV and III–IV acute graft-versus-host disease (GvHD) were 19.0% ± 0.8% and 4.8% ± 0.2%, respectively. The cumulative incidences of chronic GvHD (cGvHD) at three and five years were both 24.5% ± 1.0%, with no severe cGvHD cases. The 5-year overall survival (OS) rate was 47.1% ± 11.0%, with a median follow-up of 2037.5 days (range, 863–3488 days) among survivors. Multivariate logistic regression analysis identified not changing a donor (<i>P</i> = 0.019) as the only adverse factor for graft failure after the second HID-HSCT. Moreover, changing a donor (<i>P</i> = 0.004), compatible donor-recipient blood type (<i>P</i> = 0.005), and patient age &lt; 12 years (<i>P</i> = 0.038) at the second transplantation were significant predictors of improved OS. These findings suggest that a second HID-HSCT could be a feasible option for treating graft failure in SAA patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Ming-Hao Lin,
  • Ya-Jun Wang,
  • Yuan-Yuan Zhang,
  • Yi-Fei Cheng,
  • Yu-Qian Sun,
  • Xiao-Dong Mo,
  • Chen-Hua Yan,
  • Yu-Hong Chen,
  • Yao Chen,
  • Jing-Zhi Wang,
  • Feng-Rong Wang,
  • Ting-Ting Han,
  • Wei Han,
  • Huan Chen,
  • Yu Wang,
  • Xiao-Hui Zhang,
  • Xiao-Jun Huang,
  • Lan-Ping Xu,
  • Zheng-Li Xu

摘要

This study aimed to evaluate the outcomes of second haploidentical hematopoietic stem cell transplantation (HID-HSCT) for patients with severe aplastic anaemia (SAA) who experienced graft failure. Twenty-one SAA patients with graft failure after first allogeneic (allo-) HSCT were enrolled, including 6 (28.6%) with poor graft function and 15 (71.4%) with graft rejection. Two patients developed primary graft failure after the second transplantation, and the cumulative incidence of neutrophil recovery was 81.0% ± 0.9%, with a median recovery of 13 days (range, 10–23 days). The cumulative incidences of grade II–IV and III–IV acute graft-versus-host disease (GvHD) were 19.0% ± 0.8% and 4.8% ± 0.2%, respectively. The cumulative incidences of chronic GvHD (cGvHD) at three and five years were both 24.5% ± 1.0%, with no severe cGvHD cases. The 5-year overall survival (OS) rate was 47.1% ± 11.0%, with a median follow-up of 2037.5 days (range, 863–3488 days) among survivors. Multivariate logistic regression analysis identified not changing a donor (P = 0.019) as the only adverse factor for graft failure after the second HID-HSCT. Moreover, changing a donor (P = 0.004), compatible donor-recipient blood type (P = 0.005), and patient age < 12 years (P = 0.038) at the second transplantation were significant predictors of improved OS. These findings suggest that a second HID-HSCT could be a feasible option for treating graft failure in SAA patients.